Literature DB >> 6105516

Haemopoietic recovery in Ewing's sarcoma after intensive combination therapy and autologous marrow infusion.

R A Abrams, D Glaubiger, R Simon, A Lichter, A B Deisseroth.   

Abstract

After the completion of combination therapy designed to achieve local control of Ewing's sarcoma, 13 patients with either truncal primary lesions or proven metastases were given 150 rad of total body irradiation over 5 weeks followed by cyclophosphamide, doxorubicin, imidazole carboxamide, and vincristine. 11 patients received autologous cryopreserved marrow infusions. In 2 patients marrow collections were not attempted. Two patterns of haemopoietic recovery were observed: 8 patients, who had received marrow infusions, showed leucocyte, granulocyte, and platelet recovery by 27, 28, and 30 days. 5 patients, 3 of whom had also received marrow, showed more delayed recovery with leucocyt, granulocyte, and platelet recovery at 45, 53, and 77+ days. Delayed recovery in patients receiving marrow seemed to correlate with aberrations in marrow freezing-rate during phase change, and these aberrations could be shown to diminish post-freeze recovery of marrow granulocyte-monocyte precursor cells.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6105516     DOI: 10.1016/s0140-6736(80)90439-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  4 in total

1.  Autologous bone marrow transplantation in metastatic breast cancer.

Authors:  P S Stewart
Journal:  Breast Cancer Res Treat       Date:  1982       Impact factor: 4.872

2.  Cyclophosphamide treatment expands the circulating hematopoietic stem cell pool in dogs.

Authors:  R A Abrams; K McCormack; C Bowles; A B Deisseroth
Journal:  J Clin Invest       Date:  1981-05       Impact factor: 14.808

Review 3.  Genetic Engineering and Manufacturing of Hematopoietic Stem Cells.

Authors:  Xiuyan Wang; Isabelle Rivière
Journal:  Mol Ther Methods Clin Dev       Date:  2017-03-18       Impact factor: 6.698

4.  High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma.

Authors:  J Pritchard; T J McElwain; J Graham-Pole
Journal:  Br J Cancer       Date:  1982-01       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.